Eiji Nakano
Overview
Explore the profile of Eiji Nakano including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
62
Citations
190
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ogata D, Namikawa K, Nakano E, Fujimori M, Uchitomi Y, Higashi T, et al.
Int J Clin Oncol
. 2025 Jan;
30(2):194-198.
PMID: 39751752
Background: Melanoma is a highly malignant cancer responsible for 55 000 deaths worldwide annually. Despite its severity, its epidemiology in Japan remains understudied owing to its rarity among Asians. This...
2.
Yamazaki A, Nakano E, Yoshida T
Cureus
. 2024 Dec;
16(11):e73774.
PMID: 39677189
We report the case of a patient who experienced rheumatic immune-related adverse events (irAEs) with anti-cyclic citrullinated peptide (anti-CCP) positivity and cutaneous adverse drug reactions. A 59-year-old woman with malignant...
3.
Okuwa M, Tsujimoto M, Nakano E, Ono R, Masaki T, Fukai K, et al.
Photodermatol Photoimmunol Photomed
. 2024 Dec;
41(1):e70000.
PMID: 39673222
No abstract available.
4.
Wada S, Ishii T, Ogata D, Nakano E, Namikawa K, Yamazaki N, et al.
J Surg Oncol
. 2024 Dec;
PMID: 39648724
Malignant cutaneous adnexal tumors (MCATs) are rare. Previous population-based studies to determine the clinical features and prognosis of MCATs mainly included Caucasian patients, and the characteristics of Asian patients with...
5.
Kashihara T, Nakamura S, Yamazaki N, Takahashi A, Namikawa K, Ogata D, et al.
Radiother Oncol
. 2024 Nov;
202:110607.
PMID: 39489429
Background And Purpose: Definitive radiotherapy for patients with scalp angiosarcoma has a poor prognosis, often resulting in severe skin adverse events. Additionally, malignant melanoma is known for its radioresistant nature....
6.
Fukuda A, Ogata D, Oshima Y, Nakano E, Namikawa K, Komatsu M, et al.
J Dermatol
. 2024 Sep;
52(2):e168-e169.
PMID: 39269243
No abstract available.
7.
Tsuruta S, Ogata D, Namikawa K, Nakano E, Yamazaki N
Jpn J Clin Oncol
. 2024 Jul;
54(11):1135-1140.
PMID: 39079082
Cutaneous apocrine carcinoma is a rare skin cancer arising from apocrine sweat glands. Disease-specific treatments are required for cutaneous adnexal carcinomas due to their heterogeneous treatment responsiveness. This review reports...
8.
Manaka K, Sato J, Hikima Y, Horikoshi H, Taguchi M, Morita A, et al.
Endocr J
. 2024 Jun;
71(8):777-787.
PMID: 38839346
Central hypothyroidism and dyslipidemia are well-known adverse events (AEs) of bexarotene therapy. Although hypothyroidism is known to cause dyslipidemia, no study has examined the association between hypothyroidism and dyslipidemia in...
9.
Muto Y, Fujimura T, Takahashi A, Namikawa K, Ogata D, Nakano E, et al.
J Dermatol
. 2024 May;
51(9):1225-1232.
PMID: 38775205
Cutaneous dermatofibrosarcoma protuberans (DFSP) is a fibrohistiocytic tumor characterized by a high risk of local recurrence but a low risk of metastasis. Wide local excision (WLE) has been an important...
10.
Nakano E, Takahashi A, Ogata D, Namikawa K, Yamazaki N
J Dermatol
. 2024 May;
51(9):1199-1207.
PMID: 38716655
Most clinical trials investigating targeted therapies for patients harboring BRAF V600 mutations have included mostly White patients, and data for Asian patients are scarce. Although there are several retrospective studies...